semaglutide shortage november 2025 news Despite FDA ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market Semaglutide shortage ends as FDA

Serious but rare risks include pancreatitis with tirzepatide and lactic acidosis with metformin, particularly in patients with kidney impairment

They want a clinic that offers real support, real treatment options, and a practical path they can actually follow

Fewer side effects, better long-term adherence, sustainable weight loss

Before and after photos, along with testimonials from Semaglutide users, highlight its effectiveness in achieving and maintaining weight loss

High Dropout Rates: Clinical data shows dropout rates of 1020% within the first few months because the schedule doesn't match the user's real-world life

Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, glucagon) that remains unlicensed in the UK, with no MHRA approval, no NHS availability, and no BNF listing as of 20242025